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Background: Meta-analyses of nonrandomized studies have provided conflicting data on therapeutic hypothermia,
or targeted temperature management (TTM), at 33°C in patients successfully resuscitated after nonshockable cardiac
arrest. Nevertheless, the latest recommendations issued by the International Liaison Committee on Resuscitation
and by the European Resuscitation Council recommend therapeutic hypothermia. New data are available on the
adverse effects of therapeutic hypothermia, notably infectious complications. The risk/benefit ratio of therapeutic
hypothermia after nonshockable cardiac arrest is unclear.
Methods: HYPERION is a multicenter (22 French ICUs) trial with blinded outcome assessment in which 584 patients
with successfully resuscitated nonshockable cardiac arrest are allocated at random to either TTM between 32.5 and
33.5°C (therapeutic hypothermia) or TTM between 36.5 and 37.5°C (therapeutic normothermia) for 24 hours. Both
groups are managed with therapeutic normothermia for the next 24 hours. TTM is achieved using locally available
equipment. The primary outcome is day-90 neurological status assessed by the Cerebral Performance Categories (CPC)
Scale with dichotomization of the results (1 + 2 versus 3 + 4 + 5). The primary outcome is assessed by a blinded
psychologist during a semi-structured telephone interview of the patient or next of kin. Secondary outcomes are
day-90 mortality, hospital mortality, severe adverse events, infections, and neurocognitive performance. The planned
sample size of 584 patients will enable us to detect a 9% absolute difference in day-90 neurological status with 80%
power, assuming a 14% event rate in the control group and a two-sided Type 1 error rate of 4.9%. Two interim analyses
will be performed, after inclusion of 200 and 400 patients, respectively.
Discussion: The HYPERION trial is a multicenter, randomized, controlled, assessor-blinded, superiority trial that may
provide an answer to an issue of everyday relevance, namely, whether TTM is beneficial in comatose patients
resuscitated after nonshockable cardiac arrest. Furthermore, it will provide new data on the tolerance and adverse
events (especially infectious complications) of TTM at 32.5-33.5°C.
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Cardiac arrest remains a major cause of mortality,
as well as a cause of disability in survivors [2]. In
Europe, 300 000 cardiac arrests occur annually, of
which 250 000 are fatal. Even among patients with
good prognostic factors, less than 50% are discharged
from the hospital without severe neurological impair-
ments [3,4].
After early work suggesting a neuroprotective effect of
hypothermia [5], animal studies provided evidence of neuro-
logical recovery after a period of controlled hypothermia [6].
These findings were confirmed by two randomized trials per-
formed 10 years ago and published in the same issue of the
New England Journal of Medicine. In both trials, therapeutic
hypothermia significantly improved the neurological out-
comes of patients with cardiac arrest in shockable rhythms
(ventricular fibrillation or pulseless ventricular tachycardia).
The first randomized trial was a European multicenter study
in 275 patients managed with normothermia or hypothermia
[7]. After 6 months, the proportion of patients with good
neurological outcomes was 55% with hypothermia compared
to only 39% with normothermia (odds ratio [OR], 1.4; P=
0.009). In addition, mortality was significantly lower in the
hypothermia group (OR, 0.74; P= 0.02). The second ran-
domized trial was an Australian multicenter study in 77 pa-
tients managed with normothermia or hypothermia [8].
Again, good neurological outcomes were more common in
the hypothermia group (OR, 1.88; P= 0.046), and this differ-
ence persisted in the multivariate analysis (OR, 5.25; P=
0.011). However, hypothermia was not associated with a sig-
nificant decrease in mortality (OR, 1.75; P= 0.145). A 2012
Cochrane review and metaanalysis confirmed the neuropro-
tective effect of hypothermia (relative risk [RR] of achieving a
good neurological outcome, 1.55; 95% confidence interval
[95% CI], 1.22-1.96) [9].
These data firmly establish the efficacy of TTM be-
tween 32°C and 34°C in improving the neurological
outcomes of patients with shockable cardiac arrest.
Guidelines issued in 2010 by the European Resuscita-
tion Council (ERC) [10] and International Liaison
Committee on Resuscitation (ILCOR) [11] recommend
the routine use of TTM between 32°C and 34°C in co-
matose survivors of cardiac arrest with a nonshockable
rhythm at arrival of emergency-care providers. These
recommendations are based on a low level of evidence
(Class IIb, LOE B). No randomized trials have assessed
therapeutic hypothermia in survivors of nonshockable
cardiac arrest. The recommendations are based on
retrospective cohort studies and on prospective studies
evaluating the feasibility of achieving a period of 32°-34° TTM using invasive [12] or semi-invasive [13] devices.
Nevertheless, the results of these studies are conflicting.
– A metaanalysis [14] showed no significant improvement
in the 6-month neurological outcomes of 897 patients
included in retrospective cohorts (OR, 0.93; 95% CI,
0.88-1). In addition, two recent prospective cohort
studies not included in the meta-analysis – one from
France published in Circulation [15] and the other
from Finland published in Intensive Care Medicine
[16] – failed to demonstrate benefits from 32°-34°
TTM in survivors of nonshockable cardiac arrest.
Two German studies [17,18], one retrospective and
the other prospective, showed no decrease in mortality
when 32°-34° TTM was combined with optimal
post-cardiac arrest care (including prompt coronary
angiography if appropriate and hemodynamic parameter
optimization). A very recent post-hoc analysis of the
randomized TTM Study [19] showed no difference in
neurological outcomes in the 178 patients with
nonshockable rhythms [20].
– Other studies exhibiting similar methodological
weaknesses (retrospective or prospective
nonrandomized design without blinded assessment),
in contrast, suggest a beneficial effect of
hypothermia. Two retrospective Austrian studies
showed better neurological outcomes with 32°-34°
TTM in 374 patients [21] and 828 patients [22],
respectively, with shockable or nonshockable cardiac
arrest. Finally, a case–control study of 100 patients
with nonshockable cardiac arrest reported by an
American group showed better neurological
outcomes with 32°-34° TTM [23].
Three factors probably explain most of the difference
in 32°-34° TTM effects between patients with shockable
versus nonshockable cardiac arrest. First, patients with
shockable cardiac arrest constitute a fairly uniform
population of predominantly male individuals with a car-
diac cause (ST-segment-elevation myocardial infarction)
potentially treatable by coronary angiography and appro-
priate percutaneous coronary intervention [24]. In con-
trast, nonshockable cardiac arrest can occur in a wide
variety of settings, for instance as a complication of a
primary shockable rhythm or during asphyxia due to
hanging, drowning, or gastric-content aspiration. Sec-
ond, nonshockable cardiac arrest carries a poorer prog-
nosis than does shockable cardiac arrest: survival with
good neurological function (CPC 1 or 2) is nearly 40%
after shockable cardiac arrest compared to less than 20%
after nonshockable cardiac arrest [25,26]. Two factors
associated with a better prognosis of cardiac arrest are
less common in nonshockable than shockable rhythms,
namely, presence of a witness [27] and cardiac origin of
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effect of a therapeutic intervention requires a larger
sample size in studies of nonshockable compared to
shockable cardiac arrest. Third, a corollary to the first
and second factors is that the effects of interventions for
cardiac arrest may differ markedly between patients
with nonshockable and shockable cardiac arrest. For
example, although recent data argue against epineph-
rine treatment during shockable cardiac arrest [29,30],
other studies strongly support the earliest possible ad-
ministration of epinephrine during nonshockable car-
diac arrest [31].
Studies of neonatal hypoxia have produced convincing
evidence that 32°-34° TTM diminishes mortality and im-
proves neurological outcomes [32,33]. Although brain plas-
ticity differs between neonates and adults, this evidence
strongly supports a beneficial effect of 32°-34° TTM in
patients with cardiac arrest due only to anoxia. A
retrospective study showed that the mortality rate after
attempted suicide by hanging with cardiac arrest was
as high as 90% [34]. In contrast, in two studies of 32°-
34° TTM used to treat patients with severe asphyxia,
mortality was less than 67% [35] and 45% [36], re-
spectively. These findings support evaluation of 32°-
34° TTM in patients with nonshockable cardiac arrest
due to noncardiac causes [37].
The safety profile of 32°-34° TTM was good in two
early studies [7,8]. More recently, however, an in-
creased risk of infection [38], including pneumonia
[39] was reported. In addition, 32°-34° TTM usually
requires neuromuscular blockade, which interferes
with the neurological assessments, thereby extending
ICU stay length and diminishing the ability to identify
seizures and to provide optimal seizure prevention
[40]. Activation of the inflammatory cascade may
occur during 32°-34° TTM [41], leading to a risk of re-
bound hyperthermia, which may adversely affect pa-
tient outcomes [42,43]. Similarly, 32°-34° TTM may
exert negative hemodynamic effects, increasing vaso-
active drug requirements [44], a point of particular
concern given the poor prognosis of post-resuscitation
shock [16].
In sum, the risk/benefit ratio of 32°-34° TTM in pa-
tients with nonshockable cardiac arrest remains unclear.
This uncertainty has led to a call for randomized con-
trolled trials [45].Objectives
Primary objective
To determine whether TTM between 32.5°C and 33.5°C
(32.5°-33.5° TTM) for 24 h improves day-90 neurological
outcomes compared to TTM between 36.5°C and 37.5°C
in survivors of nonshockable cardiac arrest.Secondary objectives
To determine whether 32.5°-33.5° TTM for 24 h de-
creases mortality and morbidity (ICU and hospital stay
lengths) and to assess the safety of 32.5°-33.5° TTM.
Trial design
HYPERION is a multicenter, randomized, controlled,
assessor-blinded, superiority trial with two parallel
groups and a primary endpoint of day-90 neurological
outcome.
Methods: participants, interventions, and
outcomes
Study setting
The HYPERION trial is taking place in 22 ICUs in 22 hos-
pitals (8 university and 14 general hospitals) in France.
Eligibility criteria
Figure 1 shows the patient eligibility criteria and study
protocol.
Inclusion criteria
Patients must meet both of the following criteria:
– Cardiac arrest in nonshockable rhythm and
– Glasgow Coma Scale score ≤8. In patients receiving
sedative therapy at ICU admission, the Glasgow Coma
Scale score assessed by the emergency physician just
before sedative therapy initiation is used.
Exclusion criteria
Patients fulfilling one or more of the following criteria
are not included:
– No-flow time >10 min (time from collapse to
initiation of external cardiac massage);
– Low-flow time >60 min (time from initiation of
external cardiac massage to return of spontaneous
circulation).
– Major hemodynamic instability (defined as a
continuous epinephrine or norepinephrine infusion
at a flow rate >1 μg/Kg/min)
– Time from cardiac arrest to study inclusion >300 min
– Moribund patient
– Child C cirrhosis of the liver
– Age <18 years
– Pregnant or breastfeeding woman
– Correctional facility inmate
– Previous inclusion in another randomized clinical trial
on cardiac arrest with day-90 neurological outcome as
the primary endpoint
– Patient without health insurance
– Decision by the patient or next of kin to refuse the
study.
Figure 1 Study flowchart. ICU, intensive care unit; RRT, renal replacement therapy.
Lascarrou et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2015) 23:26 Page 4 of 12Interventions
Patients allocated at random to 32.5°-33.5° TTM have
hypothermia induced then maintained for 24 h. Slow
rewarming to 36.5°-37.5° is then achieved and main-
tained for 24 h. Patients in the control group have their
body temperature maintained at 36.5°-37.5°C for 48 h.
Figure 2 provides details on the study protocol and
randomization arms.
To induce and maintain 32.5°-33.5° TTM, each center
follows its standard protocol. Thus, the method may in-
volve active internal cooling using a specific device, ac-
tive external cooling using a specific device, or active
external cooling without a specific device. No trial using
mortality or neurological outcome as the endpoint has
demonstrated that one method is better than the others
[46,47]. Infusion of cold fluid (4°C) is recommended to
expedite achievement of the target temperature [48-50].
The same methods are used to manage hyperthermia
(above 37.5°C) in both groups. The study protocol in-
volves standardization of several parameters including
sedation, neuromuscular blockade, and management ofexpected adverse events. The use of medications (e.g.,
acetaminophen or aspirin) to maintain normothermia is
discouraged in both groups [51]. Figure 2 recapitulates
the therapeutic interventions.Concomitant medications/treatments in both groups
Sedation In the 32.5°-33.5° TTM group, all patients re-
ceive sedation with midazolam or propofol combined
with fentanyl or sufentanil according to the standard
sedation protocol in each participating ICU. Doses are
adjusted to obtain a Richmond Agitation Sedation Scale
score of −5 [52] and are tapered when body temperature
is above 36°C during the rewarming phase.
In the 36.5°-37.5° TTM group, all patients receive sed-
ation with midazolam or propofol combined with fen-
tanyl or sufentanil for the first 12 h after randomization.
Doses are adjusted to obtain a Richmond Agitation Sed-
ation Scale score of 0. As indicated in the 2010 ILCOR
guidelines [10], no data exist to support the use of seda-
tive agents during TTM at 37°C. The use of sedative
Figure 2 Inclusion criteria related to the cardiac arrest and study procedures. CA, cardiac arrest; CCCM, closed chest cardiac massage; ROSC,
return of spontaneous circulation.
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shorten the time to awakening.Shivering and neuromuscular blockade Persistent
shivering is treated according to a previously published
three-step protocol [53] that has been adapted since the
publication of the Bedside Shivering Assessment Score
(BSAS) [54,55]. The goal is to obtain a BSAS ≤1.
– Step 1, single intravenous bolus of a hypnotic agent and
an opioid, in doses equal to the hourly infusion rates of
hypnotic and opioid drugs (i.e., 5-mg intravenous
midazolam bolus if the continuous midazolam infusion
rate was 5 mg/h);
– Step 2, intravenous bolus of a nondepolarizing
neuromuscular blocker (i.e., 10 mg of
cisatracurium);
– and Step 3, continuous infusion of a nondepolarizing
neuromuscular blocker (i.e., cisatracurium in aninitial dose of 10 mg/h), with a BSAS target of ≤1;
during rewarming, the infusion may be stopped when
the core body temperature increases above 35°C.Concomitant prevention of systemic secondary brain injury
in both groups
Arterial hypotension Hemodynamic evaluations are
conducted to allow blood volume optimization. Hypo-
volemia is managed with crystalloid or colloid infusion,
according to standard practice in the participating ICU.
Subsequent evaluations are performed as dictated by the
course of the hemodynamic parameters. In accordance
with guidelines [10], and in the absence of specific ran-
domized studies, a mean arterial pressure of 65 mmHg
and, if measured, central venous oxygen saturation
(ScvO2) ≥70% are considered reasonable targets [11].
The introduction of vasoactive drug treatment is at the
discretion of the physicians, who follow international
guidelines [10] and local protocols.
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tored with the goal of maintaining SpO2 ≥ 92%, as rec-
ommended [10].
Hypercapnia and hypocapnia PaCO2 and end-tidal
partial CO2 pressure are monitored with the goal of
maintaining PaCO2 between 35 and 40 mmHg after cor-
recting for body temperature [56].
Anemia The goal is to maintain hemoglobin ≥7 g/dL in
patients without ischemic heart disease and ≥10 g/dL in
those with ischemic heart disease, as recommended [10].
Blood sugar control A protocol for monitoring blood
glucose (or capillary blood glucose) is available to the
physician in charge of the patient. In accordance with
guidelines [10], specific treatment is recommended in
patients with blood glucose values outside the 3.33-10
mmoL/L (60–180 mg/dL) range.
Withdrawal of life-sustaining treatments in both groups
Each participating ICU uses its own specific protocol to
make decisions about withdrawing life-sustaining treat-
ments. Routine evaluation of the neurological prognosis
by an out-of-house consultant is not performed. Never-
theless, to ensure that neurological outcome prediction
is performed according to the most recent evidence, our
protocol includes the following three measures [57].
1. During the trial preparation phase, all investigators
received specific instructions that decisions to
withdraw life-sustaining treatments must comply with
guidelines issued in 2012 by the ethics committee of the
French Intensive Care Society (SLRF) [58]. According to
these guidelines, multiple criteria should be used to
predict the neurological outcome. Taken individually,
the following criteria predict an unfavorable outcome
of postanoxic coma after cardiac arrest: bilateral
absence of the pupillary response to light or corneal
reflex on the third day; bilateral absence of a motor
response to pain on the third day; persistent generalized
myoclonus during the first 24 hours; an EEG
showing an isoelectric line or burst-suppression or
anoxic status epilepticus during the first week; and
bilateral absence of early cortical activity (N20)
detected by somatosensory evoked potentials after
the third day and after the end of hypothermia.
Although wrongly predicting an unfavorable outcome
cannot be entirely avoided, the risk of this occurring
can be decreased by relying on more than one criterion.
Another important point when seeking to improve
prediction accuracy is careful and exhaustive collection
of the most severe results from evaluations of each
criterion [58].2. During the trial, the investigators receive newsletters
that detail any new information on predicting
neurological outcomes after cardiac arrest and any
new French or international guidelines about
patients with coma after cardiac arrest.
3. The eCRF includes a specific section for collecting the
following data in patients with a decision to withdraw
life-sustaining treatments: clinical, laboratory, and
imaging-study findings on the day the decision was
taken; details on the decision-making process; and
details on implementation of the decision.
Outcomes
Primary outcome measure
 Neurological status 90 days after randomization
according to the CPC Scale [59-61]. The CPC is
assessed during a semi-structured telephone interview
[62]. All interviews of study patients are performed by
a single psychologist specifically trained for the study





 Day-90 quality of life evaluated using the 36-item
Short Form for Health Survey [63,64]
 Day-90 patient self-sufficiency evaluated using the
Activities of Daily Living (ADL) Index [65,66],
modified Barthel’s ADL index [67], and two simple
standardized questions [68]
 Day-90 neurocognitive status evaluated using the
telephone version of the Mini-Mental State
Examination [69]
 Estimated number of patients with symptoms of
posttraumatic stress on day 90 as assessed using the
revised Impact of Events Scale (IES) [70].
 ICU stay length
 Duration of mechanical ventilation, defined as the
time from randomization to final successful
extubation. Extubation followed by breathing
without invasive ventilatory assistance (not including
noninvasive ventilation) for 48 h is classified as
successful [71].
 Incidence of severe bleeding defined as red-blood-
cell transfusion or surgery for intracranial
hemorrhage
 Incidence of nosocomial infections in the ICU
 Incidence of aspiration pneumonia in the ICU, with
aspiration pneumonia defined as pneumonia
diagnosed within 48 h of mechanical ventilation
initiation
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ICU
 Incidence of nosocomial urinary tract infections in
the ICU
 Incidence of intravascular catheter infections in the
ICU
 Need for vasoactive drug therapy within the first 48 h
 Need for renal replacement therapy
 Number of episodes of cardiogenic pulmonary
edema
 Number of episodes of seizures
 Number of episodes of severe cardiac arrhythmia.
Participant timeline
Participant timeline is figured on Table 1.
Sample size
We expect that 14% of patients in the 36.5°-37.5° TTM
group will be CPC 1 or 2 on day 90 and that this propor-
tion will increase by 9% with 32.5°-33.5° TTM. With a two-
sided Type I error of 5% and 80% power, and given that
two interim analyses will be performed, the required num-
ber of patients is 292 per group, i.e., 584 patients in all.
Recruitment
Patient inclusion started in January 2014 in 22 French
ICUs. Enrolment is ongoing. As of February 2, 2015, 161
patients had been included.
Methods: assignment of interventions
Allocation
Randomization is centralized, web-based, and accessible
24 hours a day. Randomization is balanced (1:1) and
stratified by center and cause of cardiac arrest (probableTable 1 Participant timeline
Inclusion D













Telephone interview by psychologist
Dn: Each participant is followed until day 7 or ICU discharge, whichever occurs firstcardiac cause such as cardiac ischemia or probable non-
cardiac cause).
Sequence generation
The randomization sequence was generated by a statisti-
cian from the INSERM CIC 1415 not involved in patient
recruitment. The sequences are implemented in the soft-
ware used to collect the data (eCRF).
Blinding
Blinding of healthcare workers, patients (despite the sed-
ation), and families to the type of temperature manage-
ment is not feasible. However, the primary outcome is
assessed by a psychologist blinded to the treatment arm,
during a semi-structured telephone interview [62].
Methods: data collection, management, and
analysis
Data collection and management
The study data are recorded in an electronic web-based
case-report form (eCRF) from the medical records of
each patient (source data), by trial-site personnel. The
data manager, in cooperation with the coordinating in-
vestigator, establishes the trial database by exporting
data from the eCRF. Any protocol deviations are re-
corded in either the eCRF or the medical records.
Statistical methods
Statistical analysis
A predefined statistical analysis plan will be followed.
The intention-to-treat principle will be applied. The stat-
istical report will incorporate the data recommended by
the CONSORT Statement extension for nonpharmaco-
logic treatment interventions [72].0 D1 D2 D3 D4 Dn D90
X
X X X X X
X X X X X
X X X
X X X X X
X X X X X
X X X X X X
X
.
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randomization groups, without statistical testing. The
chi-squared test will be performed to compare the pri-
mary endpoint in the two groups. Two interim analyses
will be conducted, after the inclusion of 200 and 400 pa-
tients, respectively. The rule developed by Peto and
Haybittle [73] will be applied, with the significance level
set at 0.001 for both interim analyses and the signifi-
cance level associated with the final analysis set at 0.049
to maintain an overall Type I error of 5%.
Secondary endpoints evaluating binary variables (need
for renal replacement therapy, acute cardiogenic pul-
monary edema, and binary day-90 neurological out-
come) will be compared using the chi-squared test.
Secondary endpoints evaluating quantitative variables
(biological tests, stay lengths, and mechanical ventilation
duration) will be compared using the Student t test or
Mann–Whitney test.
Subgroup analysis
– Based on a previous trial showing that benefits from
33°C TTM in cardiac arrest were greatest in the
subgroups of patients with long no-flow times and
low-flow times (most notably longer than 15 minutes)
[74-76], we plan to perform analyses in these two
subgroups.
– We will also analyze other subgroups defined based
on the following prognostic factors: presence of a
witness (yes/no); in-hospital versus out-of-hospital
cardiac arrest; and probable cardiac origin (yes/no),
which was a stratification variable.
– Finally, to take the baseline cerebral performance
category into account, we will compare subgroups
with CPC1-2 versus CPC 3–4 before randomization.
Methods: monitoring
Data monitoring
The results of the interim analysis will be provided to the
Data and Safety Monitoring Board (DSMB), which will
make recommendations about whether to continue or stop
the trial. The DSMB is composed of 3 physicians not
otherwise involved in the trial. For both interim analyses,
the DSMB will have access to unblinded results on day-90
CPC, day-90 mortality, and secondary safety outcomes
(dialysis, infection, and seizure event). The results of the in-
terim analysis will not be disclosed unless they lead the
DSMB to request premature trial discontinuation. The
DSMB members are Prof. Pierre Francois Laterre (Depart-
ment of Critical Care Medicine, Cliniques Universitaires
Saint Luc, Université Catholique de Louvain, Avenue Hip-
pocrate, 10, 1200 Brussels, Belgium), Prof. Eric Maury
(Medical ICU, Saint-Antoine Teaching Hospital, Assistance
Publique-Hôpitaux de Paris, 184 rue du Faubourg Saint-Antoine, Cedex 12, Paris 75571, France), and Prof. Bruno
Megarbane (Medical ICU, Lariboisière Teaching Hospital,
Paris-Diderot University, Paris, France).
Harms
The trial may be temporarily stopped for an individual
patient, at the discretion of the attending physician, in
case of major serious adverse events suspected to be as-
sociated with the type of temperature management. Ac-
cording to French law, as the strategies used in both
study arms are classified as standard care, no specific
reporting procedure for unexpected serious adverse
events is planned. Follow-up data on expected serious
adverse events are recorded in the eCRF; these events
may include bleeding, cardiogenic pulmonary edema,
renal replacement therapy, infection, and withholding or
withdrawing of life-sustaining treatments.
Ethics and dissemination
Research ethics approval
The trial is conducted in compliance with the current
version of the Helsinki Declaration and good clinical
practice guidelines. The research project was approved
by the ethics committee of the French Intensive Care
Society (SRLF) on October 6, 2011, and by the appropri-
ate Ethics Committee for the Protection of Patients
(CPP Ouest 2) in Angers, France, on June 11, 2013.
Consent or assent
According to French law, because the strategies used in
both study groups are considered components of stand-
ard care, there is no requirement for consent. Instead, in-
formation of the patients or next of kin is required. All
patients assessed for enrolment in the trial are comatose
and therefore unable to understand information. Their
next of kin is informed about the trial and confirms in
writing that he/she has received this information. If no
next of kin can be contacted during screening for the
study, trial inclusion is conducted as an emergency pro-
cedure by the ICU physician, in compliance with French
law. Patients who regain consciousness are informed
about the trial as soon as possible and asked for written
confirmation that they received this information.
A patient may withdraw from the trial at any time if
the person informed about the study (patient or next of
kin) is unwilling to continue in the trial. The person
requesting trial withdrawal is asked for permission to
continue data recording and to perform the part of the
day-90 telephone interview consisting in a semi-
structured CPC assessment; patients who accept this
partial withdrawal modality have their data kept in the
study analyses. Patients who request full withdrawal have
all their data deleted.
Figure 3 Benefits from targeted temperature management in relation to patient’s prognosis.
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from the trial if the transfer occurs before the end of the
TTM phase, unless the new ICU is participating in the
trial, in which case the patient is kept in the same treat-
ment group. All patients transferred to another ICU are
followed for determination of the primary endpoint.Confidentiality
The study data will be handled as requested by the French
Data Protection Authority (Commission Nationale de l’In-
formatique et des Libertés). All original records will be kept
on file at the trial sites or the coordinating data managingFigure 4 Benefits from targeted temperature management in relation
expected in the HYPERION trial.center for 15 years. The clean electronic trial database file
will be anonymized and kept on file for 15 years.
Discussion
Few data are available to explain the discrepancies among
the findings from trials of TTM, most notably in patients
with nonshockable cardiac arrest. The beneficial effects of
32.5°-33.5° TTM probably vary with the degree of brain
damage at treatment initiation. The ischemic penumbra
concept developed for stroke is probably applicable to the
brain damage seen after cardiac arrest. In a study of pa-
tients with nonshockable cardiac arrest, the benefits from
32.5°-33.5° TTM were greatest when the no-flow time wasto patient’s prognosis documented in previous studies and
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patients with shockable or nonshockable cardiac arrest,
32.5°-33.5° TTM was most effective in the subgroup
whose time from cardiac arrest to the return of spontan-
eous circulation (ROSC) was longer than 15 minutes [74].
In a previous pilot study, 32° was better than 34° as the
target temperature [77]. The TTM Trial published in The
New England Journal Medicine [19] showed that TTM at
36°C was similar to TTM at 33°C in patients with good
prognostic factors including witnessed cardiac arrest in
shockable rhythm with short no-flow and low-flow times
compared to patients enrolled in earlier trials and having
less favorable prognostic characteristics [7,8]. Figure 3 re-
ports the estimated benefits of TTM and Figure 4 the ef-
fects documented in previous studies and the expected
effects in the HYPERION trial.
Our decision to use a 24-h period of normothermia after
32.5°-33.5° TTM was based on reports that rebound
hyperthermia adversely affected the outcomes of patients
with cardiac arrest [42,78]. Whether rebound hyperther-
mia is a causal or an associated factor for mortality or
neurological outcome after 32.5°-33.5° TTM is unclear.
However, the TTM Trial [19] established the importance
of preventing hyperthermia after cardiac arrest.
In conclusion, the HYPERION trial is the first regis-
tered randomized controlled trial evaluating the poten-
tial benefits of 32.5°-33.5° TTM on the neurological
outcome of patients after nonshockable cardiac arrest.Abbreviations
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